Trials / Completed
CompletedNCT00195598
Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder
Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VENLAFAXINE | |
| DRUG | Paroxetine |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2006-04-01
- Completion
- 2006-04-01
- First posted
- 2005-09-19
- Last updated
- 2010-04-02
Locations
4 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT00195598. Inclusion in this directory is not an endorsement.